Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients

被引:64
作者
Aktas, Bahriye [1 ]
Kasimir-Bauer, Sabine [1 ]
Mueller, Volkmar [2 ]
Janni, Wolfgang [3 ]
Fehm, Tanja [4 ]
Wallwiener, Diethelm [5 ]
Pantel, Klaus [6 ]
Tewes, Mitra [7 ]
机构
[1] Univ Duisburg Essen, Dept Gynecol & Obstet, Essen, Germany
[2] Univ Hosp Hamburg Eppendorf, Dept Gynecol & Obstet, Hamburg, Germany
[3] Univ Hosp Ulm, Dept Gynecol & Obstet, Ulm, Germany
[4] Univ Hosp Duesseldorf, Dept Gynecol & Obstet, Dusseldorf, Germany
[5] Univ Hosp Tuebingen, Dept Gynecol & Obstet, Tubingen, Germany
[6] Univ Hosp Hamburg Eppendorf, Ctr Med Expt, Inst Tumor Biol, Hamburg, Germany
[7] Univ Hosp Essen, Dept Internal Med Canc Res, Essen, Germany
来源
BMC CANCER | 2016年 / 16卷
关键词
Metastatic breast cancer; Biopsy; Metastases; Receptor expression profile; CTC; Circulating tumor cells; TISSUE CONFIRMATION; DISTANT METASTASES; PERIPHERAL-BLOOD; IMPACT; DISCORDANCE; AMPLIFICATION; TRASTUZUMAB; RECURRENCE; CONVERSION; CARCINOMA;
D O I
10.1186/s12885-016-2587-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The expression of HER2, estrogen (ER) and progesterone (PR) receptor can change during the course of the disease in breast cancer (BC). Therefore, reassessment of these markers at the time of disease progression might help to optimize treatment decisions. In this context, characterization of circulating tumor cells (CTCs) could be of relevance since metastatic tissue may be difficult to obtain for repeated analysis. Here we compared HER2/ER/PR expression profiles of primary tumors, metastases and CTCs. Methods: Ninety-six patients with metastatic BC from seven University BC Centers in Germany were enrolled in this study. Blood was obtained at the time of first diagnosis of metastatic disease or disease progression and analyzed for CTCs using the AdnaTest BreastCancer (QIAGEN Hannover GmbH, Germany) for the expression of EpCAM, MUC-1, HER2, ER and PR. HER2 expression on CTCs was additionally assessed by immunocytochemistry using the CellSearch (R) assay. Results: The detection rate for CTCs using the AdnaTest was 43 % (36/84 patients) with the expression rates of 50 % for HER2 (18/36 patients), 19 % for ER (7/36 patients) and 8 % for PR (3/36 patients), respectively. Primary tumors and CTCs displayed a concordant HER2, ER and PR status in 59 % (p = 0.262), 39 % (p = 0.51) and 44 % (p = 0.62) of cases, respectively. For metastases and CTCs, the concordance values were 67 % for HER2 (p = 0.04), 43 % for ER (p = 0.16) and 46 % for PR (p = 0.6). Using the CellSearch (R) assay, the CTC-positivity rate was 53 % (42/79 patients) with HER2 expressed in 29 % (12/42) of the patients. No significant concordance (58 % and 53 %) was found when HER2 on CTCs was compared with HER2 on primary tumors (p = 0.24) and metastases (p = 0.34). Interestingly, primary tumors and metastases were highly concordant for HER2 (84 %, p = 1.13E-08), ER (90 %, p = 3.26E-10) and PR (83 %, p = 2.09E-09) and ER-and PR-positive metastases were significantly found to be of visceral origin (p = 0.03, p = 0.02). Conclusion: Here we demonstrate that the molecular detection of HER2 overexpression in CTC is predictive of the HER2 status on metastases. Detailed analysis of ER and PR expression rates in tissue samples and CTCs may provide useful information for making treatment decisions.
引用
收藏
页数:8
相关论文
共 50 条
[31]   Prognostic Role and HER2 Expression of Circulating Tumor Cells in Peripheral Blood of Patients Prior to Radical Cystectomy: A Prospective Study [J].
Rink, Michael ;
Chun, Felix K. ;
Dahlem, Roland ;
Soave, Armin ;
Minner, Sarah ;
Hansen, Jens ;
Stoupiec, Malgorzata ;
Coith, Cornelia ;
Kluth, Luis A. ;
Ahyai, Sascha A. ;
Friedrich, Martin G. ;
Shariat, Shahrokh F. ;
Fisch, Margit ;
Pantel, Klaus ;
Riethdorf, Sabine .
EUROPEAN UROLOGY, 2012, 61 (04) :810-817
[32]   Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer [J].
Krishnamurthy, Savitri ;
Bischoff, Farideh ;
Mayer, Julie Ann ;
Wong, Karina ;
Pham, Tam ;
Kuerer, Henry ;
Lodhi, Ashutosh ;
Bhattacharyya, Anirban ;
Hall, Carolyn ;
Lucci, Anthony .
CANCER MEDICINE, 2013, 2 (02) :226-233
[33]   Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells [J].
Nini, Alessandro ;
Hoffmann, Michele Janine ;
Lampignano, Rita ;
Siemer, Robert Grosse ;
van Dalum, Guus ;
Szarvas, Tibor ;
Cotarelo, Cristina Lopez ;
Schulz, Wolfgang Arthur ;
Niederacher, Dieter ;
Neubauer, Hans ;
Stoecklein, Nikolas Hendrik ;
Niegisch, Guenter .
CYTOMETRY PART B-CLINICAL CYTOMETRY, 2020, 98 (04) :355-367
[34]   Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status [J].
Tanja Fehm ;
Sven Becker ;
Silke Duerr-Stoerzer ;
Karl Sotlar ;
Volkmar Mueller ;
Diethelm Wallwiener ;
Nancy Lane ;
Erich Solomayer ;
Jonathan Uhr .
Breast Cancer Research, 9
[35]   Expression profiling of circulating tumor cells in metastatic breast cancer [J].
Lang, Julie E. ;
Scott, Janet H. ;
Wolf, Denise M. ;
Novak, Petr ;
Punj, Vasu ;
Magbanua, Mark Jesus M. ;
Zhu, Weizhu ;
Mineyev, Neal ;
Haqq, Christopher M. ;
Crothers, Julia R. ;
Esserman, Laura J. ;
Tripathy, Debasish ;
van 't Veer, Laura ;
Park, John W. .
BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) :121-131
[36]   Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients [J].
Banys-Paluchowski, Malgorzata ;
Witzel, Isabell ;
Riethdorf, Sabine ;
Rack, Brigitte ;
Janni, Wolfgang ;
Fasching, Peter Andreas ;
Solomayer, Erich-Franz ;
Aktas, Bahriye ;
Kasimir-Bauer, Sabine ;
Pantel, Klaus ;
Fehm, Tanja ;
Mueller, Volkmar .
ANTICANCER RESEARCH, 2017, 37 (06) :3117-3128
[37]   Association of estrogen receptor, progesterone receptor and HER2 following neoadjuvant systemic treatment in breast cancer patients undergoing surgery [J].
Tsai, Y. -M. ;
Hsu, H. -M. ;
Chen, C. -J. ;
Hsu, K. -F. ;
Fan, H. -L. ;
Chang, H. ;
Chan, D. -C. ;
Yu, J. -C. .
IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 (01) :71-75
[38]   Change in estrogen receptor, HER2, and Ki-67 status between primary breast cancer and ipsilateral breast cancer tumor recurrence [J].
Okumura, Y. ;
Nishimura, R. ;
Nakatsukasa, K. ;
Yoshida, A. ;
Masuda, N. ;
Tanabe, M. ;
Shien, T. ;
Tanaka, S. ;
Arima, N. ;
Komoike, Y. ;
Taguchi, T. ;
Iwase, T. ;
Inaji, H. ;
Ishitobi, M. .
EJSO, 2015, 41 (04) :548-552
[39]   Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients [J].
Marta Pestrin ;
Silvia Bessi ;
Francesca Galardi ;
Mara Truglia ;
Annibale Biggeri ;
Chiara Biagioni ;
Silvia Cappadona ;
Laura Biganzoli ;
Augusto Giannini ;
Angelo Di Leo .
Breast Cancer Research and Treatment, 2009, 118 :523-530
[40]   Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients [J].
Giordano, Antonio ;
Giuliano, Mario ;
De Laurentiis, Michelino ;
Eleuteri, Antonio ;
Iorio, Francesco ;
Tagliaferri, Roberto ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos ;
De Placido, Sabino ;
Hess, Kenneth ;
Cristofanilli, Massimo ;
Reuben, James M. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 129 (02) :451-458